 Shares of Innate Pharma SA ADR S: ipha rallied 35.2 in premarket trading on Monday after the company said Sanofi SNY, -0.38 licensed its natural killer NK cell engager program as part of an already established collaboration between the two companies. We are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy, Valeria Fantin, Sanofis global head of oncology research, said in a news release. 